Medivation Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Leerink Partners Reit OP Rating Following Medivation (MDVN) 1Q Results
May 8, 2015 9:45 AM EDTLeerink Partners maintains an Outperform rating on Medivation, Inc. (NASDAQ: MDVN), with their price target set at $128. Leerink believes that the demand for Xtandi appears to be solid, and expects a continued uptake of Xtandi over the rest of the year. MDVN reported US Xtandi sales were $224M in 1Q15. While this was in the... More
Medivation (MDVN) PT Lifted at UBS Despite Q1 'Miss'
May 8, 2015 9:40 AM EDTUBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from $130.00) despite a miss on US Xtandi sales by $14m. The firm remain encouraged by the results since only nominal double-digit growth is required to beat 2015... More
Medivation (MDVN) Misses Q1 EPS by 10c
May 7, 2015 4:17 PM EDTMedivation (NASDAQ: MDVN) reported Q1 EPS of $0.17, $0.10 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $127.8 million versus the consensus estimate of $149 million.
U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. prior year). On its February 25, 2015 earnings call, Medivation stated its... More
